Optimización del uso de eritropoyetina con la introducción de hierro endovenoso en una unidad de hemodiálisis
- Mónica Seco Filgueira
- Isabel Calvo Castro
- Mónica Cunha Mera
- Julia Martínez Rodríguez
- Manuel Rey Varela
- Joaquín Rodríguez Seijas
- Rocío Sánchez Bello
- Teresa García Falcón
- Luis Bolaños Cea
ISSN: 1139-1375
Year of publication: 1999
Volume: 2
Issue: 2
Pages: 24-26
Type: Article
More publications in: Revista de la Sociedad Española de Enfermería Nefrológica
Abstract
The most frequent cause of a sub-optimal response to treatment with human recombinant erythropoietin (rHu-EPO) is iron deficiency. This situation must be corrected before starting treatment, and adequate levels need to be maintained. The objective of our study was to evaluate how the use of intravenous ferric gluconate in our hemodialysis unit affected rHu-EPO dosage requirements. 12 patients who had been undergoing treatment with r-Hu-EPO and Ferrlecit (ferric-gluconate) for a period of over 12 months were included in the study. The following values were analyzed: hemoglobin (Hb), hematocrit (Hto), VCH, CHCM, ferritin (Ferr), iron (Fe), transferrina saturation index (lsat), Hb/rHu-EPO coefficient, rHu-EPO dosage per patient and week (EPO U/week) and rHu-EPO dosage per kilogram of patient weight and week prior to start of Ferrlecit and at 3, 6 and 12 months. lntravenous ferric gluconate was effective in correcting the iron deficiency without secondary effects. lts use enabled us to optimize the use of erythropoietin with directly visible economic benefits since the reduction in the weekly dosage of rHu-EPO by 393 represented a saving of 254,501 pesetas per patient per year.